Early symptom improvement as a predictor of response to extended release quetiapine in major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 35, Issue 6, 2015, Pages 706-710

  McIntyre, Roger S ^a   Gorwood, Philip ^b   Thase, Michael E ^c   Liss, Charlie ^d   Desai, Dhaval ^d   Chen, Ji ^d   Bauer, Michael ^e  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ASTRAZENECA   (United Kingdom)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

early predictors; extended release quetiapine fumarate; major depressive disorder; symptom improvement

Indexed keywords

QUETIAPINE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTANTS AND COEFFICIENTS; GENERAL CONDITION IMPROVEMENT; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY (TOPIC); PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SENSITIVITY AND SPECIFICITY; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; YULE Q COEFFICIENT; DELAYED RELEASE FORMULATION; DEPRESSIVE DISORDER, MAJOR; META ANALYSIS; OUTCOME ASSESSMENT; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MULTICENTER STUDIES AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); QUETIAPINE FUMARATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84947033238     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000416     Document Type: Article

References (30)

1. Pae CU, Wang SM, Lee SY, et al. Early switch strategy in patients with major depressive disorder. Expert Rev Neurother. 2012;12: 1185-1188.
2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
3. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71:43-64.
4. Kudlow PA, Cha DS, McIntyre RS. Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. Can J Psychiatry. 2012;57:782-788.
5. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, Third edition (2010). October, 2010. Available at: http://www. psychiatryonline. com/pracGuide/ pracGuideTopic-7. aspx. Accessed September 24, 2015.
6. Hennings JM, Owashi T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients-findings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res. 2009;43:215-229.
7. Katz MM, Meyers AL, Prakash A, et al. Early symptom change prediction of remission in depression treatment. Psychopharmacol Bull. 2009;42:94-107.
8. Stassen H, Anghelescu IG, Angst J, et al. Predicting response to psychopharmacological treatment: survey of recent results. Pharmacopsychiatry. 2011;44:263-272.
9. Szegedi A, Jansen WT, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70:344-353.
10. van Calker D, Zobel I, Dykierek P, et al. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. J Affect Disord. 2009;114:243-253.
11. Gorwood P, Bayle F, Vaiva G, et al. Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. Eur Psychiatry. 2013;28:362-371.
12. Wang G, McIntyre A, EarleyWR, et al. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:201-216.
13. Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry. 2009;70: 526-539.
14. Weisler R, Joyce M, McGill L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009;14:299-313.
15. Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011;128:83-94.
16. KatilaH, Mezhebovsky I, Mulroy A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. 2013;21:769-784.
17. Liebowitz M, Lam RW, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010;27:964-976.
18. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70:540-549.
19. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13: 917-932.
20. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
21. HamiltonM. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
22. National Institute of Mental Health. CGI Clinical Global Impressions. In: Guy W, Bonato RR, eds. Manual for the ECDEU Assessment Battery.
23. Rev Ed. Chevy Chase, MD: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976;217-222.
24. Bonett DG, Price RM. Statistical inference for generalized yule coefficients in 2 - 2 contingency tables. Sociol Methods Res. 2007;35: 429-446.
25. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol. 1993;3:127-135.
26. Katz MM, Houston JP, Brannan S, et al. A multivantaged behavioural method for measuring onset and sequence of the clinical actions of antidepressants. Am Int J Neuropsychopharmacol. 2004;7: 471-479.
27. Muzina DJ, Chambers JS, Camacho TA, et al. Adjunctive aripiprazole for depression: predictive value of early assessment. Am J Manag Care. 2011;17:793-801.
28. Cha DS, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother. 2012;13:1587-1598.
29. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med. 2010;122:39-48.
30. Trivedi MH. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry. 2009; 70(suppl 6):26-31.